From the paper:
There are two types of bone disease from metastases: lytic metastases, which destroy bone tissue, and blastic metastases, which build new bone-like tissue with cancer cells. Currently, it doesn't matter if a bone metastasis is lytic or blastic -- they are both treated the same way. But the current study shows that the genetic and cellular landscapes of these two types of metastases are different, providing different drug targets and suggesting different treatments . . .
Importantly, both types of bone metastases also had characteristics that predict response to immunotherapy. Doctors and researchers call primary prostate cancers "cold," meaning they tend not to provoke an immune response. However, both blastic and lytic bone metastases had high levels of the protein PD-L1, which could mean they are more likely to respond to the class of anti-cancer immunotherapy known as checkpoint inhibitors.
"The other interesting point of our studies is that we developed a test that can directly measure immunotherapy and pathway targets in bone metastases," Owens says. "This is significant because we could potentially use this as a test to determine which of the many immunotherapies could be best for an individual patient, one at time, and truly provide a personalized therapy. If I had metastatic disease in bones, I would like a pathology department to know that the immunotherapy they wish to treat me with has a good level of target in the tissue they are hoping to treat." (emphasis added)
Science Daily article is here:
sciencedaily.com/releases/2...
Full research paper is available as PDF download using paper doi here:
Dr. Don The-Wizard Pescado's Science keeps on coming. 2020 should be a banner year for PCa developments.
Happy 2020 to All & Be Well - Captian K9
Anyhow, just wanted to clarify that my understanding is that most lytic lesions still have increased blastic activity, just not enough to compensate for the increased activity of the osteoclasts. As such, they will show up on bone scans, just not as well as a blastic lesion.
New cancer treatment immuno therapy combined with guadecitabine in lung, breast, prostate bowel cancer makes cancer visible to immune sys
